Saturday 17 October 2026 Export FOCL’s income statement to Excel — free account

FocalTherics

FocalTherics' revenue for fiscal 2025 (year ended December 2025) was $70.5 million, up 1.63% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS fell 129.4%, free cash flow grew 21.5% and total debt rose 366.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

4.15 0.02 +0.48%

Follow FOCL

Alert me

Market cap: $154.8M
P/E: 0.0×
Fwd P/E: −4.8×
Dividend yield: —
F-score: 3/9
Altman Z: −0.87
Beneish M: −3.14
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.59

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	1	—	—	8	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 154.79

Revenue 77.77

Net Income (38.97)

Free Cash Flow (19.13)

Net Debt 18.55

Current Ratio 1.60

Debt/Equity (12.43)

P/E ratio 0.00

Fwd P/E (4.84)

P/S ratio 1.90

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (33.08%)

Next Y EPS Growth 24.06%

Next Y revenue growth (26.27%)

Next 5Y EPS Growth 7.02%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 28.49%

10-year low 10-year high

EV/Sales against its own 10 years 51.35%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	47	31	20	22
Receivables	21	21	23	11
Inventory	16	19	13	8
Other	1	1	1	2
	85	73	57	59

	2023	2024	2025	Q'26
Payables	12	13	12	10
ST’ Debt	4	9	8	3
Other	2	2	2	6
	30	39	37	37

Compound Annual Growth %

	10y	5y	3y
Sales	7.01%	8.18%	6.70%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	1.94%	(8.33%)	(36.40%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	18	13	—	—	—
’25	14	10	16	31	71
’24	16	17	14	22	69
’23	16	16	13	21	65
’22	15	15	12	16	58
’21	12	12	11	16	52
’20	8	10	11	18	48

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(4)	—	—	—
’25	(5)	(5)	(4)	(2)	(16)
’24	(4)	(7)	(4)	0	(15)
’23	(3)	(6)	(2)	(5)	(16)
’22	1	0	2	(7)	(3)
’21	2	(1)	1	3	5
’20	—	—	(2)	5	2

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(5)	—	—	—
’25	(7)	(6)	(6)	(4)	(22)
’24	(5)	(7)	(6)	0	(19)
’23	(5)	(8)	(3)	(6)	(21)
’22	0	0	2	(8)	(6)
’21	1	(1)	1	2	3
’20	—	—	(4)	4	0

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.24)	(0.39)	—	—	—
’25	(0.20)	(0.17)	(0.15)	(0.25)	(0.78)
’24	(0.13)	(0.18)	(0.19)	(0.05)	(0.55)
’23	(0.22)	(0.14)	(0.12)	(0.15)	(0.62)
’22	0.01	0.06	0.00	(0.14)	(0.09)
’21	0.03	(0.02)	(0.04)	0.04	0.02
’20	(0.05)	(0.01)	(0.04)	0.03	(0.07)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2.43	2.25	1.35	1.78	1.46	5.00	5.54	3.60	2.12	1.21	Analyst estimates 2026–2028 Powerpack
	High	4.80	3.85	4.25	5.42	5.28	10.68	11.53	12.65	8.50	3.45
People
People	Employees	197	200	215	216	223	227	264	307	310	289
	Revenue/emp, $m	0.20	0.20	0.22	0.23	0.21	0.23	0.22	0.21	0.22	0.24
Income, $m
Income, $m	Revenue	39	40	46	50	48	52	58	65	69	71
	Gross margin, %	46.08	41.43	43.18	46.76	44.11	41.81	43.90	40.40	41.42	42.54
	EBT	5	0	0	2	(1)	1	(2)	(22)	(20)	(29)
	EBT margin, %	12.48	(0.82)	0.05	4.88	(2.85)	2.03	(3.80)	(33.98)	(29.21)	(40.85)
	Net income	4	(1)	0	2	(2)	1	(3)	(23)	(21)	(29)
	Depreciation	1	2	2	2	2	2	2	2	3	3
Per share, $
Per share, $	Revenue	1.42	1.40	1.60	1.73	1.63	1.62	1.69	1.77	1.86	1.88
	Earnings	0.15	(0.02)	(0.01)	0.06	(0.07)	0.02	(0.09)	(0.62)	(0.55)	(0.78)
	Cash flow	0.04	(0.12)	0.01	0.15	0.08	0.16	(0.09)	(0.43)	(0.39)	(0.44)
	Capex	(0.05)	(0.06)	(0.08)	(0.06)	(0.08)	(0.06)	(0.07)	(0.13)	(0.12)	(0.15)
	Free cash flow	0.00	(0.18)	(0.07)	0.09	0.00	0.10	(0.16)	(0.56)	(0.51)	(0.59)
	Book value	0.97	0.98	1.02	1.06	1.03	1.84	2.19	1.67	1.14	0.52
	Shares, m	28	29	29	29	29	32	34	37	37	37
Valuation, ×
Valuation, ×	P/E	20.88	0.00	0.00	84.70	0.00	247.52	0.00	0.00	0.00	0.00
	P/S	2.36	2.05	1.16	2.56	3.17	3.69	6.18	3.00	1.19	1.75
	P/B	3.43	2.91	1.82	4.20	4.69	3.38	4.70	3.19	1.94	6.35
	EV/Sales	1.92	1.64	0.83	2.21	2.67	2.84	5.12	2.37	0.91	1.78
	EV/FCF	29.78	(7.76)	(2.96)	(17.71)	97.13	56.22	(50.43)	(7.40)	(3.15)	(5.40)
Cash, $m
Cash, $m	Operating cash flow	1	(3)	0	4	2	5	(3)	(16)	(15)	(16)
	Capex	(1)	(2)	(2)	(2)	(2)	(2)	(2)	(5)	(4)	(6)
	Free cash flow	0	(5)	(2)	3	0	3	(6)	(21)	(19)	(22)
Balance, $m
Balance, $m	Working capital	28	26	28	28	27	58	72	55	33	20
	Total debt	7	6	8	6	10	10	8	7	12	24
	Net debt	(17)	(17)	(15)	(17)	(18)	(46)	(59)	(40)	(19)	4
	Shareholders’ equity	27	28	29	31	30	59	75	62	42	19
Returns, %
Returns, %	ROA	9.01	(1.47)	(0.72)	2.89	(3.18)	1.07	(3.12)	(22.29)	(21.84)	(34.73)
	ROIC	2.74	(12.11)	(6.92)	11.41	1.61	(9.18)	(16.79)	(62.22)	(60.16)	(66.17)
	ROE	19.74	(2.77)	(1.38)	5.63	(6.42)	1.86	(4.59)	(33.44)	(39.55)	(94.50)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CAH Cardinal Health, Inc.	$58.8B	35.0×	23.3×	+5.84% (above 0%: growing)	+68.32% (above 0%: growing)	+10.87% (above 0%: growing)	4.02%	1.14%	Compare
HSIC Henry Schein, Inc.	$9.7B	25.0×	18.5×	+6.73% (above 0%: growing)	+16.90% (above 0%: growing)	+140.91% (above 0%: growing)	31.84%	4.95%	Compare
AHG Akso Health Group Sponsored ADR	$1.2B	— (loss-making)	— (loss-making)	+263.89% (above 0%: growing)	n/m	−12,975.04% (below 0%: shrinking)	0.00%	0.00%	Compare
FOCL FocalTherics	$154.8M	— (loss-making)	— (loss-making)	+38.85% (above 0%: growing)	n/m	+21.49% (above 0%: growing)	55.59%	(60.83%)
COSM Cosmos Health Inc.	$33.9M	— (loss-making)	25.1×	+28.76% (above 0%: growing)	n/m	+9.39% (above 0%: growing)	7.96%	(15.41%)	Compare
ACH Accendra Health, Inc.	$20.1M	— (loss-making)	— (loss-making)	−10.07% (below 0%: shrinking)	n/m	−1,624.82% (below 0%: shrinking)	42.95%	(5.73%)	Compare
HKPD Cellyan Biotechnology Co., Ltd	$17.1M	—	—	—	—	−90.45% (below 0%: shrinking)	—	—	Compare
YI 111, Inc. Sponsored ADR	$16.0M	— (loss-making)	— (loss-making)	−29.61% (below 0%: shrinking)	n/m	−185.70% (below 0%: shrinking)	5.33%	(0.85%)	Compare
SNYRQ Synergy CHC Corp.	$1.3M	— (loss-making)	1.6×	−32.77% (below 0%: shrinking)	n/m	−148.51% (below 0%: shrinking)	72.29%	(10.32%)	Compare
Median of peers	$27.0M	—	20.9×	+5.84%	—	−119.48%	7.96%	(0.85%)

All 11 Medical Distribution stocks →

FocalTherics (FOCL) key facts

Strength: FocalTherics' revenue for fiscal 2025 (year ended December 2025) was $70.5 million, up 1.63% from fiscal 2024.
FocalTherics (FOCL) is a Medical Distribution company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, FOCL traded at $4.15, a market capitalization of $154.8 million.
Return on equity was −94.5% and debt-to-equity -12.43.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −0.87 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.